A stronger collaboration between Bristol Myers Squibb and NVIDIA aims to speed up medicine development using advanced artificial intelligence and powerful computing technology
Princeton, New Jersey, 22 July 2026 – Artificial intelligence is becoming one of the most important tools in modern healthcare, and pharmaceutical companies are investing heavily in technologies that can help develop new medicines faster. Bristol Myers Squibb has expanded its collaboration with NVIDIA to strengthen its AI capabilities and accelerate drug discovery through advanced computing infrastructure.
As part of the expanded partnership, Bristol Myers Squibb will deploy NVIDIA’s latest DGX SuperPOD system powered by the new Vera Rubin architecture. The company says this will create one of the most advanced AI computing platforms in the life sciences industry, allowing researchers to process large amounts of scientific data more quickly and efficiently.
Drug discovery is a long and expensive process that often takes years before a medicine reaches patients. Researchers must study millions of biological interactions and identify promising compounds before testing them in laboratories and clinical trials. Artificial intelligence helps simplify this work by analyzing complex datasets, identifying patterns, and predicting which drug candidates have the highest chance of success.
The expanded computing power will enable Bristol Myers Squibb scientists to evaluate a much larger number of potential drug candidates in a shorter time. Company researchers believe AI has already reduced certain stages of drug development by 20 to 30 percent, with the potential for even greater improvements as the technology continues to evolve.
The collaboration also supports research across multiple therapeutic areas, including cancer, cardiovascular diseases, and rare disorders. By combining advanced AI models with high-performance computing, scientists can gain deeper insights into disease biology, identify new treatment targets, and improve the design of future medicines.
Beyond faster research, the new AI infrastructure is expected to improve energy efficiency. Modern computing systems are designed to deliver significantly greater processing power while using energy more effectively, helping research organizations manage growing computational demands sustainably.
The announcement reflects a broader trend across the pharmaceutical industry, where artificial intelligence is becoming an essential part of research and development. Companies around the world are investing in AI platforms to improve decision-making, reduce development costs, and increase the chances of discovering successful therapies. As scientific data continues to grow, advanced computing is becoming just as important as laboratory research itself.
For patients, these technological advancements could eventually translate into faster access to innovative treatments. While every medicine must still undergo strict clinical testing and regulatory review, AI is helping researchers make smarter decisions earlier in the development process, reducing delays and improving research efficiency.
The expanded collaboration between Bristol Myers Squibb and NVIDIA highlights how artificial intelligence is reshaping the future of healthcare. As pharmaceutical companies combine scientific expertise with powerful computing technologies, the next generation of medicines may be discovered faster, developed more efficiently, and delivered to patients sooner than ever before.
